Fluocinolone acetonide implantable device for diabetic retinopathy

Current Pharmaceutical Biotechnology

Volumn 12, Issue 3, 2011, Pages 347-351

  Schwartz, Stephen G ^a   Flynn Jr , Harry W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic macular edema; Diabetic retinopathy; Fluocinolone acetonide; Randomized clinical trials; Vascular endothe lial growth factor

Indexed keywords

CORTICOSTEROID; FLUOCINOLONE ACETONIDE; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATARACT; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DOSE COMPARISON; ENDOPHTHALMITIS; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA NEOVASCULARIZATION; SIDE EFFECT; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

CATARACT; DIABETIC RETINOPATHY; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 79551679900     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111794480651     Document Type: Article

References (44)

1. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 1993, 329(14), 977-986.
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet, 1998, 352(9131), 837-853.
3. Early treatment diabetic retinopathy study research group. photoco- agulation for diabetic macular edema: Early treatment diabetic reti-nopathy study report number 1. Arch. Ophthalmol., 1985, 103(12), 1796-1806.
4. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings. DRS Report Number 8. Ophthalmology, 1981, 88(7), 583-600.
5. Schwartz, S.G.; Flynn, H.W. Jr.; Scott, I.U. Pharmacotherapy for diabetic retinopathy. Exp. Opin. Pharmacother., 2009, 10(7), 1123-1131.
6. Nauck, M.; Karakiulakis, G.; Perruchoud, A. P.; Papakonstantinou, E.; Roth, M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur. J. Pharmacol., 1998, 341(2-3), 309-315.
7. Gillies, M. C.; Simpson, J. M.; Gaston, C.; Hunt, G.; Ali, H.; Zhu, M.; Sutter, F. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology, 2009, 116(11), 2182-2187.
8. Lam, D. S.; Chan, C. K.; Mohamed, S.; Lai, T. Y.; Li, K. K.; Li, P. S.; Tsang, C. W.; Chan, W. M.; Shanmugam, M. P. A. Prospective randomized trial of different doses of intravitreal triamcinolone for diabetic macular edema. Br. J. Ophthalmol., 2007, 91(2), 199-203.
9. Lam, D. S.; Chan, C. K.; Mohamed, S.; Lai, T. Y.; Lee, V. Y.; Liu, D. T.; Li, K. K.; Li, P. S.; Shanmugam, M. P. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology, 2007, 114(12), 2162-2167.
10. Kim, J. E.; Pollack, J. S.; Miller, D. G.; Mittra, R. A.; Spaide, R. F. ISIS Study Group. ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina, 2008, 28(5), 735-740.
11. Dehghan, M. H.; Ahmadieh, H.; Ramezani, A.; Entezari, M.; Ani-sian, A. A randomized, placebo-controlled clinical trial of in-travitreal triamcinolone for refractory diabetic macular edema. Int. Ophthalmol., 2008, 28(1), 7-17.
12. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology, 2008, 115(9), 1447-1449.
13. Beck, R. W.; Edwards, A. R.; Aiello, L. P.; Bressler, N. M.; Ferris, F.; Glassman, A. R.; Hartnett, E.; Ip, M. S.; Kim, J. E.; Kollman, C. Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch. Ophthalmol., 2009, 127(3), 245-251.
14. Bressler, N. M.; Edwards, A. R.; Beck, R. W.; Flaxel, C. J.; Glass-man, A. R.; Ip, M. S.; Kollman, C.; Kuppermann, B. D. Stone, T.W. for the Diabetic Retinopathy Clinical Research Network. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triam-cinolone acetonide with focal/grid photocoagulation. Arch. Oph-thalmol., 2009, 127(12), 1566-1571.
15. Zacks, D. N.; Johnson, M. W. Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic reti-nopathy. Retina, 2005, 25(2), 135-140.
16. Bandello, F.; Polito, A.; Pognuz, D. R.; Monaco, P.; Dimastrogio-vanni, A.; Paissios, J. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopa-thy. Arch. Ophthalmol., 2006, 124(5), 643-650.
17. Margolis, R.; Singh, R. P.; Bhatnagar, P.; Kaiser, P. K. Intravitreal triamcinolone as adjunctive treatment to laser panretinal photoca-goulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema. Acta Ophthalmol., 2008, 86(1), 105-110.
18. Faghihi, H.; Taheri, A.; Farahvash, M. S.; Esfahani, M. R.; Rajabi, M.T. Intravitreal triamcinolone acetonide injection at the end of vitrectomy for diabetic vitreous hemorrhage: a randomized, clinical trial. Retina, 2008, 28(9), 1241-1246.
19. Schwartz, S. G.; Flynn, H.W.; Scott I. U. Endophthalmitis after intravitreal injections. Exp. Opin. Pharmacother., 2009, 10(13), 2119-2126.
20. Bhavsar, A. R.; Googe, J. M. Jr.; Stockdale, C. R.; Bressler, N. M.; Brucker, A. J.; Elman, M.J. Glassman, A.R.; For the Diabetic Retinopathy Clinical Research Network. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required. Arch. Ophthalmol., 2009, 127(12), 1581-1583.
21. Bhavsar, A. R.; Ip, M. S.; Glassman, A. R. DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following in-travitreal triamcinolone acetonide injection in the DRCRnet and SCORE clinical trials. Am. J. Ophthalmol., 2007, 144(3), 454-456.
22. Aggermann, T.; Stolba, U.; Brunner, S.; Binder, S. Endophthalmitis with retinal necrosis following intravitreal triamcinolone acetonide injection. Ophthalmologica, 2006, 220(2), 131-133.
23. Murray, R. J.; Aravena-Roman, M.; Kampfer, P. Endophthalmitis due to Williamsia muralis. J. Med. Microbiol., 2007, 56(10),1410
24. Saidel, M. A.; Berreen, J. Margolis, T. P. Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am. J. Ophthalmol., 2005, 140(6), 1141-1143.
25. Roth, D. B.; Flynn, H.W. Jr. Distinguishing between infectious and noninfectious endophthalmitis after intravitreal triamcinolone injection. Am. J. Ophthalmol., 2008, 146(3), 346-347.
26. Gillies, M. C.; Sutter, F. K.; Simpson, J.M.; Larsson, J.; Ali, H.; Zhu, M. Intravitreal triamcinolone acetonide for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology, 2006, 113(9), 1533-1538.
27. Thompson, J.T. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am. J. Ophthalmol., 2006, 141(4), 629-637.
28. Smithen, L.M.; Ober, M.D.; Maranan, L.; Spaide, R.F. Intravitreal triamcinolone and intraocular pressure. Am. J. Ophthalmol., 2004, 138(5), 740-743.
29. Rhee D. J.; Peck, R. E.; Belmont, J.; Martidis, A.; Liu, M.; Chang, J.; Fontanarosa, J.; Moster, M. R. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br. J. Ophthalmol., 2006, 90(8), 999-1003.
30. Becker, B. Intraocular pressure response to topical corticosteroids. Invest. Ophthalmol., 1965, 4(2), 198-205.
31. Gerzenstein, S. M.; Pletcher, M. T.; Cervino, A. C.; Tsinoremas, N. F.; Young, B.; Puliafito, C. A.; Fini, M. E.; Schwartz, S. G. Gluco-corticoid receptor polymorphisms and intraocular pressure response to intravitreal triamcinolone acetonide. Ophthalmic Genet., 2008, 29(4), 166-170.
32. Jaffe, G.J.; Martin, D.; Callanan, D.; Pearson, PA.; Levy, B.; Com-stock, T. Fluocinolone Acetonide Uveitis Study Group. Fluoci-nolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology, 2006, 113(6), 1020-1027.
33. Callanan, D.G.; Jaffe, G.J.; Martin, D.F.; Pearson, P.A.; Comstock, T.L. Treatment of posterior uveitis with a fluocinolone implant: three-year clinical trial results. Arch. Ophthalmol., 2008, 126(9), 1191-1201.
34. Kane, F.E.; Burdan, J.; Cutino, A.; Green, K.E. Iluvien: a new sustained delivery technology for posterior eye disease. Exp. Opin. Drug Deliv., 2008, 5(9), 1039-1046.
35. Kuppermann, B.D.; Blumekranz, M.S.; Haller, J.A.; Williams, G.A.; Weinberg, D.V.; Chou, C.; Whitcup, S.M.; Dexamethasone, D.D.S. Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol., 2007, 125(3), 309-317.
36. Ayalasomayajula, S.P.; Ashton, P.; Kompella, U.B. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM). J. Ocul. Pharmacol. Ther., 2009, 25(2), 97-103.
37. No authors listed. Fluocinolone acetonide ophthalmic - Bausch & Lomb: fluocinolone acetonide Envision TD implant. Drugs RD, 2005, 6(2), 116-119.
38. Montero, J. A.; Ruiz-Moreno, J. M. Intravitreal inserts of steroids to treat diabetic macular edema. Curr. Diabetes Rev., 2009, 5(1), 26-32.
39. Chieh, J.J.; Carlson, A.N.; Jaffe, G.J. Combined fluocinolone ace-tonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis. Arch. Oph-thalmol., 2008, 146(4), 589-594.
40. Goldstein, D.A.; Godfrey, DG.; Hall, A.; Callana, D.G.; Jaffee, G.J.; Pearson, P.A.; Usner, D.W.; Comstock, T.L. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch. Ophthalmol., 2007, 125(11), 1478-1485.
41. Bollinger, K.E.; Smith, S.D. Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant. Curr. Opin. Ophthalmol., 2009, 20(2), 99-103.
42. Yeh, S.; Cebulla, C. M.; Witherspoon, S. R.; Emerson, G.G.; Emerson, M. V.; Suhler, E.B.; Albini, T. A.; Flaxel, C. J. Management of fluocinolone implant dissociation during implant exchange. Arch. Ophthalmol., 2009, 127(9), 1218-1221.
43. Ufret-Vincenty, R. L.; Singh, R.P.; Lowder, C.Y.; Kaiser, P.K. Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. Am. J. Ophthalmol., 2007, 143(2), 334-335.
44. Sims, J.L.; Chee, S.P. Cytomegalovirus endotheliitis following fluocinolone acetonide (Retisert) implant. Eye, 2010, 24(1), 197-198.